Cybin Corporation is a mushroom life sciences company founded in 2019. The Canadian-based firm encompasses two divisions: Serenity Life Science and Nature’s Journey. Serenity develops psilocybin-based pharmaceutical treatments for addiction disorders and mental illness. Nature’s Journey produces proprietary, non-psychedelic fungi-based nutraceuticals intended to “optimize overall health.” NetworkNewsWire coverage called Cybin Corp “one to watch” in July 2020.
On its website, Cybin describes its intellectual property strategy as revolving around “psychedelic delivery mechanisms, synthetic compounds, extraction methods, isolation of chemical compounds, new drug formulations and protocol regimens.” The company aims to pioneer novel administrations of psilocybin, including efficient, low-dose, dissolvable sublingual strips.
In February of 2020, Cybin partnered with the Toronto Centre for Psychedelic Science to execute clinical trials. In a press release announcing the partnership, former Cybin CEO Paul Glavine stated, “While there is evidence to support psilocybin as a treatment for certain indications, the Toronto Centre for Psychedelic Science is taking a clinical approach to prove or disprove the safety and efficacy of psilocybin-based microdosing through an open science approach.”
Doug Drysdale was appointed Cybin’s Chief Executive Officer in September 2020.